ENVALITH
クオールホールディングス株式会社 logo

Qol Holdings Co., Ltd.

3034・Prime Market・Retail Trade

Official website
クオールホールディングス株式会社 logo
Qol Holdings Co., Ltd.3034

Business

Qol Holdings Corporation is a healthcare services holding company with 28 consolidated subsidiaries. In its core Pharmacy Business, it operates 949 insurance pharmacies nationwide, while its BPO Business provides healthcare-related outsourcing services including CSO, CRO, referral staffing, and publishing-related operations. In its Pharmaceutical Business, the company manufactures and sells pharmaceuticals centered on AG products, with Daiichi Sankyo Espha Co., Ltd. (80% equity stake) as its core entity. Consolidated net sales for FY2026 (ending March 2026) were ¥290,772 million, with the business composition being 61% Pharmacy Business, 34% Pharmaceutical Business, and 5% BPO Business. A key characteristic is its integrated value chain spanning from upstream (pharmaceuticals) to downstream (pharmacy) in healthcare.

Business Model

The pharmacy business is a stable-type model with dispensing fee revenue (technical fees) and drug sales revenue as its main income sources. The pharmaceutical business achieves high growth through the manufacture and sale of AG (authorized generic) products based on exclusive distribution agreements with brand-name manufacturers. The BPO business earns revenue from service fees for MR (medical representative) staffing, recruitment placement, CRO outsourcing, and similar services. Group synergies across the three businesses (such as providing pharmaceutical MR information leveraging pharmacy know-how, and pharmacist staffing placement) form a competitive advantage.

Company Strengths

As of the end of FY2026 (ending March 2026), the company operated 949 stores, recording pharmacy business revenue of ¥177,461 million. The number of collaborative stores with Lawson reached 50 in April 2026, demonstrating a unique model of integration with convenience stores. The company has also continued M&A of firms specializing in home-based dispensing, enhancing its presence as regional healthcare infrastructure.

Since the equity-method application began in October 2023, the company gradually increased its equity stake, reaching 80% in April 2025. In FY2026 (ending March 2026), pharmaceutical business revenue reached ¥99,010 million (up 25.8% year on year), with operating profit of ¥6,960 million (up 32.0% year on year), achieving high growth. Exclusive distribution agreements (each for 10 years) with Bayer and AstraZeneca have secured a stable product pipeline.

The company holds three businesses—pharmacy (downstream), BPO (intermediary support), and pharmaceuticals (upstream)—diversifying single-business risk. In FY2026 (ending March 2026), both revenue and profit at each stage reached record highs. EBITDA reached ¥24,624 million (up 12.8% year on year), improving the group's overall earnings generation capability.

ENVALITH's Perspective

For FY2026 (ending March 2026), the company achieved record-high results with net sales of ¥290,772 million (up 10.2% year-on-year), operating income of ¥14,811 million (up 10.0%), and net income attributable to owners of the parent of ¥7,408 million (up 43.5%). The substantial increase in net income was mainly due to the disappearance of extraordinary losses recorded in the previous period, including officer retirement benefits of ¥964 million and a loss on step acquisition of ¥214 million, as well as a decrease in profit attributable to non-controlling interests from ¥2,312 million to ¥1,064 million following the increase in the equity stake in Daiichi Sankyo Espha. It should be noted that this reflects a combination of genuine operational improvement and structural factors.

The Pharmacy Business secured revenue growth, with net sales of ¥177,461 million (up 3.4% year-on-year), but segment profit declined to ¥9,730 million (down 3.0%). The main cause was an increase in personnel costs resulting from wage increases implemented in response to inflation, compounded by sluggish growth in the number of dispensing transactions due to longer prescription periods. As an external factor, the newly established Medical DX Promotion System Development Add-on introduced in the FY2024 dispensing fee revision has pushed up the unit price of technical fees, but this has not been enough to offset the rise in personnel costs. Restoring the profitability of the Pharmacy Business going forward is a critical issue that will determine the group's overall profit level.

Against the FY2031 (ending March 2031) targets of consolidated net sales of ¥500.0 billion and operating income of ¥35.0 billion, actual results for FY2026 (ending March 2026) were net sales of ¥290,772 million and operating income of ¥14,811 million, meaning that achieving the targets would require approximately 1.7x growth in net sales and approximately 2.4x growth in operating income over the five-year period. While continued introduction of new AG products and expansion into areas beyond generic drugs will be key growth drivers for the Pharmaceutical Business, the core Pharmacy Business is projected to achieve steady growth in FY2027 (ending March 2027), with forecast net sales of ¥315,000 million and operating income of ¥16,500 million. However, cash flow from financing activities showed an outflow of ¥14,966 million (including ¥7,250 million for the additional acquisition of Daiichi Sankyo Espha shares), causing cash and cash equivalents to decrease to ¥20,988 million. Attention should be paid to the balance between future M&A capacity and financial discipline.

Growth Strategy

Aiming for net sales of ¥500.0 billion in FY2031 (ending March 2031) through deepening and evolution of the three businesses of pharmacy, BPO, and pharmaceuticals

First Sankyo Espha will continue to launch AG (authorized generic) products (5 products across 2 components launched and manufacturing/marketing approval obtained for 4 products across 2 components in FY2026), expand into areas beyond generic drugs, and promote market share growth by leveraging know-how from the pharmacy business to provide information.

The company aims to absorb rising personnel costs and restore profitability in the pharmacy business through the use of cloud-based electronic medication history systems, zero-based cost reviews, and productivity improvements driven by DX promotion. It will also address functional differentiation by promoting certification acquisition as community cooperation pharmacies and specialized medical institution cooperation pharmacies.

The pharmacy network will be expanded through strategic M&A and new store openings. In FY2026 (ending March 2026), the company built a network of 949 stores through a net increase of 19 stores, comprising 10 new store openings, 8 business transfers, and 1 subsidiarization. M&A activity to strengthen home-visit and institutional dispensing, such as the acquisition of shares in Yokohama Yakugyo Service Co., Ltd., which is proactive in home-visit dispensing, will continue.

The company will promote improved profit margins in the CSO business through an increase in the number of MRs dispatched and revision of dispatch unit prices, expansion of the CRO business through the use of EDC (electronic data capture) by Clin Cloud Co., Ltd. (which joined the group in November 2025), and productivity improvements through AI utilization in the placement and staffing business, along with expansion of new businesses (spot pharmacist dispatch and occupational physician-related services).

Under the basic policy of "Deepening and Evolution," the company aims to achieve consolidated net sales of ¥500.0 billion and operating profit of ¥35.0 billion in FY2031 (ending March 2031) through the development and growth of its three businesses: pharmacy, BPO, and pharmaceuticals. It will concurrently pursue environmental impact reduction and promotion of the SDGs toward realizing sustainability.

Last updated: July 19, 2026